Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 4/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.39 |
| ▸ | GOT1 | P17174 | 1/20 | 0.39 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.39 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632562 | 1.00 | MTNR1A (0.51) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL20980913 | 0.78 | MTNR1A (0.49) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL13345363 | 0.78 | MTNR1A (0.49) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL10173839 | 0.78 | MTNR1A (0.49) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL430325 | 0.77 | SLC6A2 (0.49) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL27903505 | 0.77 | AADAT (0.42) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL4798469 | 0.77 | SLC6A2 (0.49) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL23917061 | 0.77 | NOTUM (0.39) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL6341407 | 0.77 | MTNR1A (0.62) | MTNR1AMTNR1BNOTUMHTR2AHTR2C | |
| SCHEMBL11667313 | 0.77 | MTNR1A (0.56) | MTNR1AMTNR1BNOTUMESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192375-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2020113071-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020028706-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-3140291-A2 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2017-03-15 | — | — | EP | disclosed |
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-7910751-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | MOCHIDA PHARMACEUTICAL CO.,LTD (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | TRPV1, TRPV3, TRPA1 | MTNR1A 507/4885MTNR1B 871/4885NOTUM 1696/4885 |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | TRPV1, TRPV3, TRPA1 | MTNR1A 507/4885MTNR1B 871/4885NOTUM 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.